Cellectar Biosciences
CLRB
6 hedge funds and large institutions have $6.87M invested in Cellectar Biosciences in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
31% more capital invested
Capital invested by funds: $5.23M → $6.87M (+$1.64M)
0% more funds holding
Funds holding: 6 → 6 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$231K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$224K |
| 3 |
SC
Sophrosyne Capital
New York
|
-$77K |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $4.38M | +$5.7M | +74 | New |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $1.64M | – | – | – |
|
|
SC
3
Sophrosyne Capital
New York
| $441K | -$77K | -1 | -17% |
|
|
4
Goldman Sachs
New York
| $193K | +$154K | +2 | New |
|
|
BA
5
Bard Associates
Chicago,
Illinois
| $133K | – | – | – |
|
|
VKH
6
Virtu KCG Holdings
New York
| $44K | – | – | – |
|
7
Morgan Stanley
New York
| $29K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $3K | – | – | – |
|
|
SSB
9
Sandy Spring Bank
Olney,
Maryland
| $2K | – | – | – |
|
|
SM
10
Sabby Management
Miami Beach,
Florida
| $1.92K | -$231K | -3 | -13% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
AIG
12
American International Group
New York
| $15 | – | – | – |
|
|
13
Fidelity Investments
Boston,
Massachusetts
| – | -$224K | -3 | Closed |
|
|
KCM
14
Knoll Capital Management
Miami,
Florida
| – | -$33K | – | – |
|
CLRB Hedge Fund Activity: Q4 2014 in Review
6 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2014, worth a combined $6.87M — up 31% from $5.23M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CLRB positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $154K. The largest seller was Sabby Management, cutting an estimated $231K.
- 6 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $6.87M of Cellectar Biosciences stock for Q4 2014, up 31% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q4 2014 and 1 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences buyer in Q4 2014 was Goldman Sachs, an estimated $154K added.
- The largest Cellectar Biosciences seller in Q4 2014 was Sabby Management, an estimated $231K sold.
Based on aggregated 13F filings for Q4 2014.